2010 full-year results 3 March 2011 - UCB
2010 full-year results 3 March 2011 - UCB
2010 full-year results 3 March 2011 - UCB
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Neupro ® in the U.S.<br />
Parkinson’s disease & restless legs syndrome<br />
FDA Complete Response Letter (December 2008)<br />
• “Substantial evidence of effectiveness in advanced Parkinson’s disease and<br />
restless legs syndrome”<br />
Development of room temperature-stable patch<br />
formulation on track<br />
Complete Response Letter recommending reformulation<br />
(April <strong>2010</strong>)<br />
• <strong>UCB</strong> aims to bring Neupro ® to U.S. patients during 2012<br />
Neupro ®<br />
Parkinson’s disease<br />
Neupro ®<br />
Restless legs syndrome<br />
Christer, living with<br />
Parkinson’s disease<br />
Approved Launched<br />
Phase 1 Phase 2 Phase 3 Filed<br />
Filed<br />
CRL*<br />
Dec. 2008<br />
CRL*<br />
Dec. 2008<br />
* Complete Response Letter<br />
72
Change language